Ardelyx, Inc. (ARDX) Earnings Call Transcripts

Ardelyx, Inc.'s Latest Earnings Call - Q1 FY2026

In the first quarter of 2026, Ardelyx, Inc. reported total product revenues of $93.4 million, marking a 38% increase year-over-year, driven primarily by a 58% surge in IBSRELA sales to $70.1 million. The company reiterated its full-year revenue guidance for IBSRELA and XPHOZAH, expecting IBSRELA to generate between $410 million and $430 million, reflecting a 50% to 57% growth. Management expressed confidence in their strategy and ability to capture market opportunities, particularly emphasizing the strong demand for IBSRELA despite seasonal challenges.

Reported metrics

Guidance from management

Management reiterated its revenue guidance for IBSRELA between $410 million and $430 million for 2026, expecting continued quarter-over-quarter growth. XPHOZAH is also expected to generate between $110 million and $120 million in revenue for the year.

What management said

Sure. I'll ask Eric to comment a bit on it. But for us, seeing what we all went through in the first quarter, which is normal seasonality in those 2 storms, seeing that continued growth in demand only strengthens our conviction in terms of where we're seeing this business grow and very, very pleased with those results. Eric, anything to add?

Yes. Thanks, Roanna, for the question. Very pleased with what we saw in terms of demand in Q1 and very similar to the patterns that we've seen in the past. We expect to continue to see quarter-over-quarter growth as we move forward. I feel very confident with the team that we have in place and continuing to invest in access and making sure that all patients that are written a prescription can get fulfillment. So I fe...

What analysts pressed on

Analysts expressed concerns about operational expenses, particularly with the ramp-up of the Phase III CIC trial and its impact on cash flow. Additionally, there were questions regarding the competitive dynamics in the IBS-C market and how Ardelyx plans to maintain its growth trajectory amid potential competition.

Main topics on the call

• IBSRELA Revenue Growth — IBSRELA achieved a remarkable 58% year-over-year revenue growth, driven by increased prescription demand. Management stated, "Our disciplined commercial execution drove 58% year-over-year revenue growth," reinforcing con...
• XPHOZAH Performance — XPHOZAH's revenue remained stable at $23.3 million, consistent with the prior year, but adjusted for a favorable return reserve in Q1 2025, it reflects a 19% growth. Management noted, "Our paid prescriptions of XPHOZAH r...
• Pipeline Expansion — The initiation of the ACCEL trial for IBSRELA in chronic idiopathic constipation (CIC) is a key focus, with enrollment expected to complete by year-end 2026. Management highlighted, "We remain on track to complete enroll...
• Financial Guidance Reiteration — Ardelyx maintained its revenue guidance for 2026, projecting IBSRELA revenues between $410 million and $430 million. CFO Sue Hohenleitner stated, "We are reiterating our 2026 revenue guidance for IBSRELA between $410 mil...

Read the full Ardelyx, Inc. transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 32 Ardelyx, Inc. earnings call transcripts on record, spanning February 24, 2021 to August 6, 2026. Based on this history, Ardelyx, Inc. reports quarterly. The most recent call on file is dated August 6, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

ARDX

Exchange

NasdaqGM

Country

US

Sector

Health Care

Industry

Biotechnology

Calls on record

32

First call

February 24, 2021

Most recent

August 6, 2026

Reporting cadence

quarterly